Kinarus Therapeutics Holding AG
SIX:KNRS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.896
30.464
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Kinarus Therapeutics Holding AG
Kinarus Therapeutics Holding AG
Total Liabilities & Equity
Kinarus Therapeutics Holding AG
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kinarus Therapeutics Holding AG
SIX:KNRS
|
Total Liabilities & Equity
CHf111k
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
N/A
|
|
|
Wizz Air Holdings PLC
LSE:WIZZ
|
Total Liabilities & Equity
€8.7B
|
CAGR 3-Years
23%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
Kinarus Therapeutics Holding AG
Glance View
Kinarus Therapeutics Holding AG is a Swiss biopharmaceutical company at the forefront of innovative drug development, particularly in the realm of advanced therapies for respiratory and viral diseases. Founded with the mission to address significant unmet medical needs, Kinarus is pioneering the use of its proprietary therapeutic platform that targets mechanisms associated with chronic and infectious conditions. The company is making strides with its lead candidate, KIN001, a novel treatment designed to combat COVID-19 while also addressing the long-term implications of the disease, illustrating Kinarus’s commitment to not only responding to immediate health crises but also improving patient outcomes over the long term. Investors will find Kinarus's strategic focus compelling, as it centers on leveraging its unique drug candidates to tap into lucrative markets with expansive potential for growth. The company collaborates with academic institutions and industry partners, reinforcing its innovative edge and enhancing its research capabilities. Positioned in the robust European biotechnology landscape and with a skilled leadership team that emphasizes sustainable development, Kinarus stands out as an attractive investment opportunity for those looking to engage in the life sciences sector. Through its advancements, Kinarus aims to deliver both breakthrough therapies and significant shareholder value, making it a noteworthy player in the ever-evolving healthcare market.
See Also
What is Kinarus Therapeutics Holding AG's Total Liabilities & Equity?
Total Liabilities & Equity
111k
CHF
Based on the financial report for Dec 31, 2023, Kinarus Therapeutics Holding AG's Total Liabilities & Equity amounts to 111k CHF.
What is Kinarus Therapeutics Holding AG's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
-45%
Over the last year, the Total Liabilities & Equity growth was -99%. The average annual Total Liabilities & Equity growth rates for Kinarus Therapeutics Holding AG have been -4% over the past three years , -45% over the past five years .
You don't have any saved screeners yet
